The global COVID-19 diagnostics market size reached USD 58.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 29.0 Billion by 2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Market Size in 2024
|
USD 58.3 Billion |
Market Forecast in 2033
|
USD 29.0 Billion |
COVID-19 diagnostics refer to the clinical tests conducted to detect the presence of the viral infection among individuals. COVID-19 is an infectious disease caused by the newly discovered zoonotic coronavirus. Some common symptoms include fever, fatigue, dry cough, shortness of breath, sore throat and body aches. The viral infection is usually diagnosed through reverse transcriptase-polymerase chain reaction (RT- PCR), antigen-based and antibody testing. These tests use reagents and kits to obtain the sample from nasopharyngeal (NP), oropharyngeal (OP) and nasal swabs, human saliva or blood. They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.
The sudden outbreak of coronavirus disease and an alarming increase in the number of COVID-19 cases across the globe are among the key factors creating a positive outlook for the market growth. The continuous rise in the number of daily cases has led to the widespread adoption of diagnostic tests for rapid and comprehensive testing to provide early treatment to the patients. In line with this, the increasing demand for mass testing and molecular diagnostics is contributing to the market growth. Additionally, various product innovations, such as the launch of novel antibody and serology test kits for home-testing, are acting as other growth-inducing factors. In comparison to the traditionally used testing kits, these variants are less time-consuming and can be integrated with software-based programs for accurate results. Other factors, including the implementation of favorable government polices to prevent the further spread of COVID-19 infection, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global COVID-19 diagnostics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on product type, sample type, test type, mode and end use.
Breakup by Product Type:
Breakup by Sample Type:
Breakup by Test Type:
Breakup by Mode:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft and Thermo Fisher Scientific Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product Type, Sample Type, Test Type, Mode, End Use, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft, Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global COVID-19 diagnostics market was valued at USD 58.3 Billion in 2024.
Due to the sudden outbreak of the COVID-19 and the increasing number of cases, there has been a rising demand for COVID-19 diagnostics for rapid and comprehensive testing to provide early treatment to the coronavirus infected patients.
The rising demand for mass testing and molecular diagnostics, along with the advent of novel antibody and serology test kits for home-testing, is primarily driving the global COVID-19 diagnostics market.
Based on the product type, the global COVID-19 diagnostics market can be segmented into reagents and kits, instruments, and others. Currently, instruments hold the majority of the total market share.
Based on the sample type, the global COVID-19 diagnostics market has been divided into nasopharyngeal swabs, oropharyngeal swabs, nasal swabs, blood, and others. Among these, nasopharyngeal swabs currently exhibit a clear dominance in the market.
Based on the test type, the global COVID-19 diagnostics market can be categorized into molecular (RT-PCR) testing, antigen-based testing, antibody (serology) testing, and others. Currently, molecular (RT-PCR) testing accounts for the majority of the global market share.
Based on the mode, the global COVID-19 diagnostics market has been segregated into Point-of-Care (PoC) and Non-Point-of-Care (Non-PoC), where Non-Point-of-Care (Non-PoC) currently holds the largest market share.
Based on the end use, the global COVID-19 diagnostics market can be bifurcated into laboratories, hospitals, diagnostic centers and clinics, and others. Currently, laboratories exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global COVID-19 diagnostics market include Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft, and Thermo Fisher Scientific Inc.